A lab technician visually inspects a filled vial of investigational coronavirus disease treatment drug remdesivir at a Gilead Sciences facility in La Verne, California.
' sales fell 10% in the second quarter from a year earlier as demand fell for some of its drugs because of the coronavirus pandemic.
Gilead's total product sales slid 10% to $5.1 billion in the second quarter, down from $5.6 billion a year ago and less than the $5.31 billion analysts expected. The company reported adjusted earnings of $1.11 per share, lower than the $1.45 per share projected by analysts surveyed by Refinitiv. "The impact of COVID-19 on Gilead's business continues to be subject to a high degree of uncertainty given unpredictable dynamics related to the incidence, spread and efforts to treat COVID-19 around the world," the company wrote in its earnings release.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Barclays Profit Falls as Covid-19 Hits U.K. UnitBarclays net profit fell 91% in the second quarter after its U.K. unit swung to a loss because of the impact of the coronavirus pandemic.
Read more »
Bill Gates: U.S. 'sadly' not taking coronavirus ‘seriously’Billionaire philanthropist Bill Gates warned that U.S. failure to take the coronavirus “seriously” could have even more dire consequences when the fall brings conditions conducive to the spread of the pandemic.
Read more »
Faces of some of the more than 150,000 lives lost in US to coronavirusBREAKING: The U.S. death toll for the coronavirus has climbed over the grim milestone of 150,000—more than the deadliest flu season in recent years.
Read more »
GE loses less cash than expected even as pandemic pummels earningsGeneral Electric Co lost less cash than estimated in the second quarter even as the coronavirus pandemic pummeled demand in its aviation business, resulting in a wider-than-expected quarterly loss.
Read more »
Starbucks shares jump as investors shrug off coffee chain's loss and hope worst of the pandemic is behind it“We’ve accelerated some strategic initiatives that really future-proof the company,” Starbucks CEO Kevin Johnson says about the coronavirus impact.
Read more »